Citation Impact
Citing Papers
Reactive Oxygen Species in Inflammation and Tissue Injury
2013 Standout
Tadalafil Therapy for Pulmonary Arterial Hypertension
2009 Standout
Current oral treatments for erectile dysfunction
2002
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin
2005 Standout
Binding of Tritiated Sildenafil, Tadalafil, or Vardenafil to the Phosphodiesterase-5 Catalytic Site Displays Potency, Specificity, Heterogeneity, and cGMP Stimulation
2004
Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline
2010 Standout
Nitric oxide synthases: regulation and function
2011 Standout
Phosphodiesterase-5 Inhibition: the Molecular Biology of Erectile Function and Dysfunction
2005
Update on Phosphodiesterase (PDE) Isoenzymes as Pharmacologic Targets in Urology: Present and Future
2006
Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents
2005 Standout
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
2006 Standout
Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management
2010
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension
2004
Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis
2013 Standout
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
2005 Standout
Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide
2006
Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications
2005
Overview of phosphodiesterase 5 inhibition in erectile dysfunction
2003
cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
2010 Standout
Lack of Exercise Is a Major Cause of Chronic Diseases
2012 Standout
PDE5 is converted to an activated state upon cGMP binding to the GAF A domain
2003
Exercise training ameliorates the impairment of endothelial and nitrergic corpus cavernosum responses in diabetic rats
2010
Sexual dysfunction in men and women with endocrine disorders
2007
Hydrogen sulphide and its therapeutic potential
2007 Standout
Potency, selectivity, and consequences of nonselectivity of PDE inhibition
2004
Implications of PDE4 structure on inhibitor selectivity across PDE families
2004
Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction
2002
Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance
2004
The Role of Nitric Oxide in Erectile Dysfunction: Implications for Medical Therapy
2006
Endothelial dysfunction in diabetic erectile dysfunction
2006
The Thromboxane/Endoperoxide Receptor (TP): The Common Villain
2010
Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed
2012 Standout
Diabetic Neuropathies
2005 Standout
Vardenafil, a New Phosphodiesterase Type 5 Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes
2003
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
2002
Inhibition of the tonic contraction in the treatment of erectile dysfunction
2003
Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function
2003
Pharmacology of Penile Erection
2001
Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions
2005 Standout
Mechanisms of Diabetic Complications
2013 Standout
Ca2+Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase
2003 Standout
Biomedical Importance of Indoles
2013 Standout
Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease
2003
Prostaglandins and Inflammation
2011 Standout
Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide Signaling
2007 Standout
Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells
2002
Works of A Allona being referenced
Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF
2003
Current role of penile implants for erectile dysfunction
2004
Activation and potentiation of the NO/cGMP pathway by NG‐hydroxyl‐L ‐arginine in rabbit corpus cavernosum under normoxic and hypoxic conditions and ageing
2003
Enhanced Thromboxane Receptor-Mediated Responses and Impaired Endothelium-Dependent Relaxation in Human Corpus Cavernosum from Diabetic Impotent Men: Role of Protein Kinase C Activity
2006
The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil
2001
Diabetes Exacerbates the Functional Deficiency of NO/cGMP Pathway Associated with Erectile Dysfunction in Human Corpus Cavernosum and Penile Arteries
2009
Rationale for the Combination of PGE1 andS-Nitroso-glutathione to Induce Relaxation of Human Penile Smooth Muscle
2000